Literature DB >> 21247612

Stem cell-based anti-HIV gene therapy.

Scott G Kitchen1, Saki Shimizu, Dong Sung An.   

Abstract

Human stem cell-based therapeutic intervention strategies for treating HIV infection have recently undergone a renaissance as a major focus of investigation. Unlike most conventional antiviral therapies, genetically engineered hematopoietic stem cells possess the capacity for prolonged self-renewal that would continuously produce protected immune cells to fight against HIV. A successful strategy therefore has the potential to stably control and ultimately eradicate HIV from patients by a single or minimal treatment. Recent progress in the development of new technologies and clinical trials sets the stage for the current generation of gene therapy approaches to combat HIV infection. In this review, we will discuss two major approaches that are currently underway in the development of stem cell-based gene therapy to target HIV: one that focuses on the protection of cells from productive infection with HIV, and the other that focuses on targeting immune cells to directly combat HIV infection.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21247612      PMCID: PMC3072166          DOI: 10.1016/j.virol.2010.12.039

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  170 in total

1.  Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance.

Authors:  Joseph Anderson; Akhil Banerjea; Ramesh Akkina
Journal:  Oligonucleotides       Date:  2003

2.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

3.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

4.  Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

Authors:  Jan van Lunzen; Tobias Glaunsinger; Ingrid Stahmer; Volker von Baehr; Christopher Baum; Andrea Schilz; Klaus Kuehlcke; Sonja Naundorf; Holger Martinius; Felix Hermann; Tsanan Giroglou; Sebastian Newrzela; Ingrid Müller; Francis Brauer; Gunda Brandenburg; Alexander Alexandrov; Dorothee von Laer
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

5.  Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.

Authors:  Aviva Joseph; Jian Hua Zheng; Ken Chen; Monica Dutta; Cindy Chen; Gabriela Stiegler; Renate Kunert; Antonia Follenzi; Harris Goldstein
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

6.  Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.

Authors:  Cesar A Virgen; Zerina Kratovac; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Authors:  Janine Kimpel; Stephen E Braun; Gang Qiu; Fay Eng Wong; Michelle Conolle; Jörn E Schmitz; Christian Brendel; Laurent M Humeau; Boro Dropulic; John J Rossi; Annemarie Berger; Dorothee von Laer; R Paul Johnson
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

8.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Authors:  Rafael G Amado; Ronald T Mitsuyasu; Joseph D Rosenblatt; Frances K Ngok; Andreas Bakker; Steve Cole; Nathalie Chorn; Lii-Shin Lin; Gregory Bristol; Maureen P Boyd; Janet L MacPherson; Gregory C Fanning; Alison V Todd; Julie A Ely; Jerome A Zack; Geoff P Symonds
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

Review 9.  Passive immunization as tool to identify protective HIV-1 Env epitopes.

Authors:  Victor G Kramer; Nagadenahalli B Siddappa; Ruth M Ruprecht
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

10.  Evolution of a TRIM5-CypA splice isoform in old world monkeys.

Authors:  Ruchi M Newman; Laura Hall; Andrea Kirmaier; Lu-Ann Pozzi; Erez Pery; Michael Farzan; Shawn P O'Neil; Welkin Johnson
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823

View more
  21 in total

1.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

Review 2.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

3.  Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.

Authors:  Zhenya Ni; David A Knorr; Laura Bendzick; Jeremy Allred; Dan S Kaufman
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

Review 4.  Cell-based gene therapy against HIV.

Authors:  R Dey; B Pillai
Journal:  Gene Ther       Date:  2015-06-16       Impact factor: 5.250

Review 5.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

6.  Engineering HIV-Specific Immunity with Chimeric Antigen Receptors.

Authors:  Scott G Kitchen; Jerome A Zack
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

7.  HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

Authors:  Anjie Zhen; Masakazu Kamata; Valerie Rezek; Jonathan Rick; Bernard Levin; Saro Kasparian; Irvin Sy Chen; Otto O Yang; Jerome A Zack; Scott G Kitchen
Journal:  Mol Ther       Date:  2015-06-08       Impact factor: 11.454

8.  Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model.

Authors:  Sofie Vets; Janine Kimpel; Andreas Volk; Jan De Rijck; Rik Schrijvers; Bert Verbinnen; Wim Maes; Dorothee Von Laer; Zeger Debyser; Rik Gijsbers
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

9.  Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.

Authors:  Sawitree Nangola; Agathe Urvoas; Marie Valerio-Lepiniec; Wannisa Khamaikawin; Supachai Sakkhachornphop; Saw-See Hong; Pierre Boulanger; Philippe Minard; Chatchai Tayapiwatana
Journal:  Retrovirology       Date:  2012-02-20       Impact factor: 4.602

Review 10.  The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.

Authors:  Bradford K Berges; Mark R Rowan
Journal:  Retrovirology       Date:  2011-08-11       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.